Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke university experience

Cancer

Volumn 116, Issue 20, 2010, Pages 4711-4717

  Tang, Ping ^a   Sun, Leon ^a   Uhlman, Matthew A ^a   Polascik, Thomas J ^a   Freedland, Stephen J ^a,b,c   Moul, Judd W ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Mortality; Predictor; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RACE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CAUSE OF DEATH; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; RISK FACTOR;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 78349300559     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25447     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin. 2009;59:264-273.
3. Andriole GL, Grubb RL III, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
4. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
5. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534. (Pubitemid 43898816)
6. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289-294.
7. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25:431-436. (Pubitemid 350002992)
8. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007;99:526-532. (Pubitemid 47073555)
9. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
10. Bell DS, Hays RD, Hoffman JR, Day FC, Higa JK, Wilkes MS. A test of knowledge about prostate cancer screening. Online pilot evaluation among Southern California Physicians. J Gen Intern Med. 2006;21:310-314.
11. Berg AO. Screening for prostate cancer: recommendations and rationale. Am J Nurs. 2003;103:107-110.
12. U. S. Preventive Services Task Force. Screening for prostate cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185-191.
13. Cooperberg MR, Konety BR. Management of localized prostate cancer in men over 65 years. Curr Opin Urol. 2009;19:309-314.
14. Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly-when to stop? J Urol. 2009;181:1606-1614; discussion 1613-1614.
15. Kuller LH, Thomas A, Grandits G, Neaton JD. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:373-377. (Pubitemid 38737461)
16. Connolly D, Black A, Gavin A, Keane PF, Murray LJ. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev. 2008;17:271-278. (Pubitemid 351272775)
17. Carroll P, Albertsen PC, Greene K, et al. Prostate-specific antigen best practice statement: 2009 update. Available at: http://www.auanet.org/content/ media/psa09.pdf?CFID= 2222 669&CFTOKEN=51763703&jsessionid= 8430dbd8c441c8 fbff084730349766b37275. Accessed July 8, 2009.
18. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology. NCCN stresses importance of PSA testing in high-risk men. Available at: www.nccn. org/about/news/newsinfo.asp?NewsID = 218. Updated on August 10, 2009. Accessed January 1, 2010.
19. Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology. 2001;57:83-90. (Pubitemid 32065825)